Clinigen Group plc UK supply & distribution agreement with PAION
02 Setembro 2021 - 9:00AM
RNS Non-Regulatory
TIDMCLIN
Clinigen Group plc
02 September 2021
2(nd) September 2021
Clinigen signs exclusive UK supply and distribution agreement
with PAION
Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global
pharmaceutical Services and Products company, announces it has
signed an exclusive partnership agreement with PAION for the supply
and distribution of key products into the UK.
The first product within the agreement will be Byfavo(R)
(remimazolam) which has been approved by the European Commission in
the EU in March 2021 and by the Medicines & Healthcare products
Regulatory Agency (MHRA) in the UK in June 2021. Byfavo(R) is the
first product developed by PAION to be approved and launched in
Europe. In addition, PAION has two further products, GIAPREZA(R)
(angiotensin II) and XERAVA(R) (eravacycline), in its portfolio
that have also been launched recently outside the UK.
Under the terms of the agreement Clinigen will manage the supply
and distribution of PAION's licensed products in the UK.
Sam Herbert, Chief Operating Officer and Head of Products
Division, Clinigen, said:
"We are pleased to be partnering with PAION for their first
commercial launch in the UK and to be able to offer Byfavo(R) to
healthcare providers across the UK through our lifecycle platform .
We look forward to building a long and successful relationship with
PAION that can help patients in the UK get access to the healthcare
they need."
Katja Lundell, UK General Manager, PAION, said:
"We are delighted to partner with Clinigen for the commercial
launch of Byfavo, leveraging their strong regulatory, supply and
distribution capabilities to ensure broad access of this important
product in the UK. We look forward to working with them on this and
our other products."
- Ends -
Contact details
Clinigen Group plc +44 (0) 1283 495010
Sam Herbert, investors@clinigengroup.com
Group Chief Operating Officer & Head of Products
Division
Rob Fox, VP Investor Relations and Corporate
Development
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Jessica Tel: +44 (0) 20 3709 5700
Hodgson Clinigen@consilium-comms.com
PAION Tel: +44 (0) 7464 544 995
Katja Lundell, UK General Manager k.lundell@paion.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist
pharmaceutical services and products company focused on providing
ethical access to medicines. Its' mission is to deliver the right
medicine to the right patient at the right time. The Group operates
from sites in North America, Europe, Africa and the Asia
Pacific.
Clinigen has more than 1,000 employees across five continents in
16 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 34 of the top 50 pharmaceutical companies; interacting
with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit
http://www.clinigen.com
About PAION
PAION AG is a publicly listed specialty pharmaceutical company
with innovative drugs to be used in hospital-based sedation,
anesthesia and critical care services. PAION's lead compound is
remimazolam, an intravenous, ultra-short-acting and controllable
benzodiazepine sedative/anesthetic. Remimazolam is approved in the
U.S., the EU/EEA/UK and China for procedural sedation and in Japan
and South Korea for general anesthesia.
In addition to Byfavo(R) (remimazolam), PAION has two further
products, GIAPREZA(R) (angiotensin II) and XERAVA(R)
(eravacycline), in its portfolio. GIAPREZA(R) is a vasoconstrictor
indicated for the treatment of refractory hypotension in adults
with septic or other distributive shock who remain hypotensive
despite adequate volume restitution and application of
catecholamines and other available vasopressor therapies. XERAVA(R)
is a novel fluorocycline type of antibiotic indicated for the
treatment of complicated intra-abdominal infections in adults.
PAION's mission is to be a leading specialty pharmaceutical
company in the fields of anesthesia and critical care by bringing
novel products to market to benefit patients, doctors and other
stakeholders in healthcare.
About Byfavo(R)
This product is subject to additional monitoring which will
allow quick identification of new safety information . A copy of
the Summary of Product Characteristics can be accessed at
https://www.medicines.org.uk/emc/product/12746/smpc#gref.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASSSFSEEFSELU
(END) Dow Jones Newswires
September 02, 2021 08:00 ET (12:00 GMT)
Clinigen (LSE:CLIN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Clinigen (LSE:CLIN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
